Concord Drugs Ltd
₹71.00
as on
What are INDmoney investors doing with Concord Drugs shares?
Based on platform-user behaviour - not analyst opinion or company fundamentals.
Search interest on INDmoney
+11%
Searches for Concord Drugs on INDmoney have increased by 11% over the last 30 days.
Concord Drugs Stock Performance
as on November 13, 2026 at 9:31 pm IST
Day's High
₹71.00₹73.503.52%
Upside
52 Week's Low
52 Week's High
₹59.99₹92.52
15.51%
Downside
30.31%
Upside
Concord Drugs share price movements today
- Previous Close
- ₹72.95
- Open
- ₹72.99
- Volume
- 4,218.00
- Upper Circuit
- ₹87.54
- Lower Circuit
- ₹58.36
- Day's Low - High
- ₹71.00 - ₹73.50
- 52 Week Low - High
- ₹59.99 - ₹92.52
Concord Drugs Historical Returns
- 1 Month Return
- -0.01 %
- 3 Month Return
- + 1.82 %
- 1 Year Return
- -17.42 %
- 3 Year Return
- + 117.21 %
- 5 Year Return
- + 131.97 %
Concord Drugs Fundamentals
as on November 13, 2026 at 4:01 pm IST
Market Cap
₹94.44 Cr
Return on Equity (ROE)
2.52
PE Ratio (TTM)
31.03
Return on capital employed (ROCE)
4.94
Industry PE ratio
54.89
Beta (LTM)
0.48
P/B Ratio
1.98
Dividend Yield
0PEG Ratio
17.94
Quarterly Earnings Growth YOY
478.95
EPS (TTM)
0.8
Book Value
35.43
Concord Drugs Stock Valuation
as on November 13, 2026 at 4:01 pm IST
Concord Drugs in the last 5 years
Lowest (-961.50x)
January 3, 2025
Today (31.03x)
November 13, 2026
Industry (54.89x)
November 13, 2026
Highest (791.40x)
July 3, 2024
Today’s Price to Earnings Ratio: 31.03x
Concord Drugs Technical Analysis
Track how Concord Drugs technical analysis has moved over time to understand its trends.
Technicals Summary
Bearish
Neutral
Bullish
Moving Averages
Bearish
Neutral
Bullish
Oscillators
Bearish
Neutral
Bullish
Overall
Oscillators
Name | Value | Action |
|---|---|---|
MACD level (12,26) | -0.33 | |
CCI (20) | -221.49 | Bullish |
RSI (14) | 6.56 | Bullish |
Momentum (10) | -1 | Neutral |
ADI (14) | 58.29 | |
Ultimate Oscillator (7,14,28) | 0 |
Moving Averages
Name | Value | Action |
|---|---|---|
SMA (20) | 71.8 | |
EMA (20) | 71.77 | |
VWMA (20) | 71.65 | |
SMA (50) | 72.35 | |
EMA (50) | 71.98 | |
SMA (200) | 71.66 | |
EMA (200) | 71.92 | |
KAMA (200) | 72.28 | |
DEMA (200) | 71.7 |
Concord Drugs Ltd vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Concord Drugs with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| NA | 94.44 | 26.39% | 0.63 | 1 | 78 | |
| NA | 99.93 | 17.27% | 0.89 | -24 | 28 | |
| NA | 1,472.93 | 18.98% | 0.00 | 43 | 349 | |
| NA | 229.83 | 7.3% | 0.64 | 20 | 172 | |
| BUY | 15,358.11 | 11.27% | 0.73 | 397 | 8,279 |
Concord Drugs Ltd Quarterly Profit & Loss
Figures in Rupees Crores
Concord Drugs Ltd Annual Profit & Loss
Figures in Rupees Crores
Concord Drugs Ltd Cash Flow
Figures in Rupees Crores
Concord Drugs Corporate Actions
View detailed summary of the earnings and dividend history of Concord Drugs.
Concord Drugs Ltd Earnings Results
Concord Drugs Ltd’s net profit jumped 478.95% since last year same period to ₹1.10Cr in the Q2 2026-2027. On a quarterly growth basis, Concord Drugs Ltd has generated -0.9% fall in its net profits since last 3-months.
Read More
Insights on Concord Drugs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 years, Concord Drugs stock has moved up by 117.2%
NO EFFECTRetail Holding Unchanged
Retail Investor holdings remained unchanged at 54.92% of holdings in Sep 2026 quarter
- NO EFFECT
Against Peers
In the last 1 year, Laurus Labs Ltd has given 137.2% return, outperforming this stock by 154.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 45.08% of holdings in Sep 2026 quarter
- NO EFFECT
Against Peers
In the last 3 years, Laurus Labs Ltd has given 555.2% return, outperforming this stock by 438.0%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 3 quarters, 37.9 Cr → 20.81 Cr (in ₹), with an average decrease of 22.7% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.11 Cr → 1.1 Cr (in ₹), with an average decrease of 0.9% per quarter
About Concord Drugs Ltd
Revenue: ₹20.75Cr as on September 2026 (Q2 FY27)
Net Profit: ₹1.10Cr as on September 2026 (Q2 FY27)
Chairperson Name: S Nagi Reddy
| Organisation | Concord Drugs Ltd |
| Industry | Pharmaceuticals |
| CEO | S Nagi Reddy |
| E-voting on shares | Click here to vote |
FAQs
What is Concord Drugs share price today?
Concord Drugs share price today stands at ₹71 as on at the close of the market. Concord Drugs share today touched a day high of ₹73.5 and a low of ₹71.
What is the 52 week high and 52 week low range for Concord Drugs share?
Concord Drugs touched a 52 week high of ₹92.52 and a 52 week low of ₹59.99. Concord Drugs share price today i.e. is closed at ₹71, which is -23.26% down from its 52 week high and 18.35% up from its 52 week low.
What is Concord Drugs's market capitalisation today?
Concord Drugs market capitalisation is ₹94.44 Cr as on .
How to buy Concord Drugs shares?
To buy Concord Drugs shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for 538965 or Concord Drugs Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Concord Drugs shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is Concord Drugs trading volume today?
Concord Drugs trading volume is 4,218.00 as on . This means that 4,218.00 shares of Concord Drugs were bought and sold on the stock market during today's trading session.